University of Nebraska - Lincoln

DigitalCommons@University of Nebraska - Lincoln
Dissertations and Theses in Biological Sciences

Biological Sciences, School of

8-2012

Characterization of Binding and Fusion Efficiencies Mediated by
the V1-V5 Env Derived from Transmitted and Non-transmitted
Viruses Isolated from a Perinatal Transmission Cohort from
Zambia
Mackenzie Waltke
University of Nebraska-Lincoln, Mwaltke@huskers.unl.edu

Follow this and additional works at: https://digitalcommons.unl.edu/bioscidiss
Part of the Virology Commons

Waltke, Mackenzie, "Characterization of Binding and Fusion Efficiencies Mediated by the V1-V5 Env
Derived from Transmitted and Non-transmitted Viruses Isolated from a Perinatal Transmission Cohort
from Zambia" (2012). Dissertations and Theses in Biological Sciences. 45.
https://digitalcommons.unl.edu/bioscidiss/45

This Article is brought to you for free and open access by the Biological Sciences, School of at
DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Dissertations and Theses in
Biological Sciences by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.

CHARACTERIZATION OF BINDING AND FUSION EFFICIENCIES
MEDIATED BY THE V1-V5 REGION OF HIV-1 ENV DERIVED FROM
TRANSMITTED AND NON-TRANSMITTED VIRUSES ISOLATED FROM A
PERINATAL TRANSMISSION COHORT FROM ZAMBIA

by

Mackenzie Waltke

A THESIS

Presented to the Faculty of
The Graduate College at the University of Nebraska
In Partial Fulfillment of Requirements
For the Degree of Master of Science

Major: Biological Sciences
Under the Supervision of Professor Charles Wood

Lincoln, Nebraska

August, 2012

CHARACTERIZATION OF BINDING AND FUSION EFFICIENCIES
MEDIATED BY THE V1-V5 REGION OF HIV-1 ENV DERIVED FROM
TRANSMITTED AND NON-TRANSMITTED VIRUSES ISOLATED FROM A
PERINATAL TRANSMISSION COHORT FROM ZAMBIA
Mackenzie Waltke, M.S.
University of Nebraska, 2012
Advisor: Charles Wood

Abstract: Human Immunodeficiency Virus Type 1 (HIV-1) is the etiological agent of
acquired immunodeficiency syndrome (AIDS), which affects over 34 million people
worldwide. In sub-Saharan Africa where access to antiretroviral therapies (ART) is
limited, mother-to-child transmission (MTCT) rates remain high and represent a major
concern in the global HIV/AIDS epidemic. Little is known about the biological properties
of viruses that are transmitted perinatally, including how the biological functions of
envelope (Env) influence transmissibility. Previously, transmitted viruses were found to
have an advantage in replicative fitness mediated by Env V1-V5. In this study viruses
derived from transmitting mother infant pairs (MIPs) were used to determine if the
binding and fusion activities are influenced by Env V1-V5 and if any differences
correlate to replicative fitness and transmission. Fusion and binding assays were used to
measure the biological functions of Env from individual clones of five MIP. RESULTS:
Neither binding nor fusion is predictive of transmission. However, clonal variation in
both functions is observed, demonstrating V1-V5 is capable of influencing fusion and
binding. Fusion correlates with infectivity, but does not correlate with binding. The

results of this study have provided new insights to better understand the functional
properties of Env and its role in MTCT.
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Chapter 1: Literature Review

Overview of HIV-1 and the Global AIDS epidemic
Human immunodeficiency virus (HIV) is the etiological agent of acquired
immunodeficiency syndrome (AIDS). The United Nations Program on AIDS (UNAIDS)
estimated that as of 2010 there were 34 million people living with AIDS. Due to
successes in increasing access to antiretroviral therapies (ART) worldwide, both the
number of new HIV infections and AIDS-related deaths have decreased over the last
decade. Another success has been an increase in access to HIV testing and counseling.
However, testing in low- and middle-income countries still remains problematic. Women
and children remain under-served in terms of testing and access to ART. Women also
remain more affected by HIV than men in sub-Saharan Africa. Several other populations,
for example men who have sex with men, remain also underserved. Low- and middleincome countries with HIV/AIDS epidemics have made progress in increasing the
availability of ART, but ultimately remain insufficient. Moving forward in the effort to
combat the global HIV/AIDS epidemic, early detection of infection and early access to
ART remained vital [WHO, 2011]. HIV-1 is a lentivirus within the retroviridae family.
The HIV-1 genome has three major genes (gag, pol, and env) and a number of accessory
genes. HIV-1 infects primarily CD4+ T cells and monocyte/macrophage lineage cells.
Viral entry into host cells is initiated by the engagement of the receptor, CD4, and the
coreceptor, CCR5 or CXCR4, by the envelope glycoprotein (Env) spike, a heterotrimer
of three glycoprotein 120 molecules (gp120) bound to three transmembrane glycoprotein
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41s (gp41). Following the binding events a conformational change induces fusion of the
viral and cellular membranes that allows the HIV-1 core to be delivered to the cytoplasm.
Once in the cytosol, the viral RNA is reverse transcribed into double-stranded DNA. The
viral DNA is translocated into the nucleus and integrated into the host cell chromosomal
DNA. This integrated DNA drives the transcription of viral RNA which is then
transported to the cytoplasm to be translated. Newly synthesized viral proteins and two
copies of the full length genomic RNA are assembled into new viral particles. As these
particles are released, cleavage of the viral protein into the mature form takes place to
generate the mature virions capable of initiating new infection.
Transmission of HIV-1 occurs through sexual and non-sexual routes. Sexual
transmission remains the major route of HIV-1 transmission in sub-Saharan Africa and
globally [WHO, 2011]. Both heterosexual and homosexual transmission across mucosal
epithelial cells is common. Many factors contribute to the risk of sexual transmission
including the disease status of the transmitting partner, the susceptibility of the recipient
partner, the number exposures, the type of sexual act, and characteristics of the
transmitted virus. Viral load of the index partner is a major risk factor in sexual
transmission. Viral load in genital secretions is also a determinant during sexual
transmission. Often viral levels in both the female genital tract and in semen correlate
with plasma viral loads. Acute infection, late-stage disease, and other infections are all
factors that can increase HIV-1 concentrations in the blood and are risk factors for sexual
transmission. The presence of STIs or other conditions that are capable of disrupting the
mucosal layer in the genital tract that leads to an increase in sexual transmission [Galvin
and Cohen, 2004].

3

Mother to child transmission and the HIV/AIDS Epidemic
Another major route of HIV transmission is perinatal transmission. UNAIDS
estimated in 2008 that there were over two million children living with HIV.
Approximately 90% of these children were infected during pregnancy, birth, or through
breastfeeding [Ahmad, 2000; UNAIDS, 2008]. Recent programs to prevent mother to
child transmission (MTCT) as well as access to ART have achieved a measure of success
at limiting new child infections of HIV and child deaths due to AIDS [WHO, 2011].
However, as of 2010 there were still 390,000 new HIV infections in children under 15,
only 35% of pregnant women were tested for HIV, and 48% of HIV positive pregnant
women were receiving some form of antiretroviral treatment. A majority of these new
pediatric infections occurred in sub-Saharan Africa [WHO, 2011]. In countries with the
highest HIV prevalence, it is the underlying cause of one-third of the deaths of children
under the age of five [Bennnett and Rogers, 1991; WHO, 2011]. In many developing
countries and in the absence of ART, perinatal transmission rates remain between 3045% [Bulterys and Lepage, 1998; Lathey et al, 1999]; this is of particular concern in subSaharan Africa where access to ART is still limited and HIV-1 infection is epidemic
[Cooper et al, 2002]. MTCT remains a major concern in the global fight against
HIV/AIDS.
Routes and risk factors for perinatal transmission
HIV perinatal transmission occurs through three routes; intrauterine, intrapartum,
and during breast feeding. However, these routes are hard to distinguish and mechanisms
underlying perinatal are not well-understood. It is likely that interplay between host and
viral factors will play important roles in perinatal transmission. Maternal parameters that
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could influence MTCT include advanced clinical stages of the disease, a low CD4+
lymphocyte count, a high level of circulating HIV-1, and disease progression. Also,
maternal immune response to HIV-1 and recent infection have been implicated as risk
factors for perinatal transmission [Adjorlolo-Johnson et al, 1994; Newell, 1995; Ryder et
al, 1989; Study, 1994]. Studies indicate that an elevated viral load in the mother plays a
role in MTCT [Cao et al, 1997; Garcia et al, 1999; Newell and Peckham, 1993]. Acute
infection during pregnancy, the presence of sexually transmitted diseases or other chronic
infections, and the disruption of placental integrity are also associated with perinatal
transmission [Newell, 1993; Report, 1992]. Some studies provide evidence that vitamin
A deficiency, malnutrition that lead to immunodeficiency, and disruption of mucosal
integrity, are all associated with an increased risk of perinatal transmission of HIV-1
[Semba, 1997].
Intrauterine transmission
It is often difficult to distinguish between the routes of perinatal transmission;
while some studies point to specific risk factors associated with each route, these results
still remain controversial. A number of studies have shown that HIV is capable of
infecting the placenta at all stages of pregnancy. HIV-1 has been isolated from aborted
fetuses as early as 8 weeks of gestation, indicating that early in utero transmission also
takes place [Lewis, 1990]; however, the risk of placental infection appears to be more
likely during late pregnancy. Placental disruption, secondary to chorioamnionitis or
smoking, has been associated with increased risk of transmission [Newell, 1995].
Generally, diagnosis of in utero infection involves HIV-1 that can be detected by virus
culture or PCR in peripheral blood within 48 hours of birth [Lewis, 1990]. Intrauterine
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transmission could also occur during late pregnancy, and HIV-1 may not be detectable in
infant plasma for several days to a week after birth, and therefore a negative PCR test at
birth cannot exclude in utero transmission [Dunn et al, 2000].
Intrapartum transmission
Many factors important in intrauterine transmission can also increase the risk for
intrapartum transmission. They include maternal plasma viral load, lack of antiretroviral
use during pregnancy, and ascending infections from the vagina/cervix to fetal
membranes and amniotic fluid [Newell, 1995]. HIV has been cultured from cellular and
cell-free fractions of vaginal and endocervical secretions. There is some evidence that the
excretion of HIV in these secretions is higher in pregnant women [UNAIDS, 2008], thus
enhancing the risk of intrapartum transmission. Overall, intrapartum transmission rates
range from ~10-20% and transmission during delivery accounts for ~2/3 of infant
infections. Obstetrical considerations, including mode of delivery, may alter the duration
of ruptured membranes and was shown to have an effect on the risk of HIV transmission
[Newell and Peckham, 1993]. Unique risk factors influencing transmission during the
intrapartum period include genital tract HIV-1 levels, genital ulcer disease, delivery
complications, and breaks in the placental barrier. Another recently reported risk factor
during delivery is placental microtransfusions, which were found to be associated with
increased intrapartum but not in utero transmission [Kwiek et al, 2006].
Transmission during breastfeeding
Infection via breastfeeding is difficult to determine closely following parturition,
because it is hard to distinguish breast milk transmission from late intrauterine or
intrapartum infections. It is estimated that as many as one-third to one-half of the infants
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infected with HIV-1 were infected via breast milk [UNAIDS, 2008]. In countries where
alternatives to breastfeeding are not available, overall transmission risk increases to 3045% [Rousseau et al, 2004; Thorne and Newell, 2003]. A meta-analysis of nine cohorts
of HIV-1 infected breastfeeding mothers reported that infant infections attributable to
breastfeeding during the first month following birth was 24~42% [Coutsoudis et al,
2004]. Two of the most important determinants of breast milk transmission risk are
duration of breastfeeding and HIV-1 viral levels in breast milk. In general, breast milk
HIV-1 RNA concentrations are 2-3 log10 lower than levels in plasma, ranging from
undetectable to greater than 105 log10 copies/ml, and are highly correlated with plasma
HIV-1 viral load [Rousseau et al, 2004]. Local inflammation resulting from mastitis,
breast abscess, or other pathology may increase breast milk virus levels and the risk of
transmission [John et al, 2001]. It is still unclear if transmission occurs through HIV
infected cells in breast milk or through cell-free HIV in breast milk. Chronic or acute
maternal infection does not appear to play a role in the risk of transmitting the virus to
offspring via breastfeeding [Newell, 1995].
Host genetic factors
Maternal and infant genetic factors also play a role in MTCT. Human leukocyte
antigen (HLA) concordance between the mother and infant increases the risk of
transmission [Mackelprang et al, 2008; Polycarpou et al, 2002]. Certain variations in
HLA have been shown to be associated with MTCT. Mothers with certain HLA- B
(1302, 3501, 3503, 4402, 5001) variants were shown to transmit to their children even
with low viral loads. Mothers with HLA-B 4901 and 5301 showed a lower risk of
transmission even with high viral loads [Winchester et al, 2004]. Another study found
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that mother-infant pairs that were discordant for HLA-G variants 3743 C/T, 634 C/G, and
714insG/G had a decreased risk for transmission [Aikhionbare et al, 2006].
The structure and function of CCR5 in both mothers and infants also influences
MTCT. Modifications of CCR5, such as a 32-bp deletion from the coding region (∆32)
provide protection from infection. Individuals homozygous for ∆32 have almost complete
protection from infection. Some studies support protection from MTCT in heterozygous
infants [Kostrikis et al, 1999], while others do not [Misrahi et al, 1998]. The chemokine
CCL3 is a natural ligand for CCR5 and acts as a potent agonist against HIV-1. CCL3
produced by both infants and mothers affects transmission. Infants that produce less
CCL3 were more susceptible to HIV-1 infection than infants that were exposed to HIV-1
and produced high amounts of CCL3. Similarly, mothers that produced less CCL3 were
more likely to transmit [Meddows-Taylor et al, 2006].
Up regulation of CCR5 in the placenta may be related to transmission. Behbahani
et. al. [2000] found a four-fold increase in the ratio of CCR5:CXCR4 expression in the
placenta from transmitting mothers compared to non-transmitting mothers. Studies
carried out with a MTCT cohort from Malawi showed that polymorphisms in the CCR5
gene were related to an increase in CCR5 expression in the placenta; however, they were
unable to show that this increase in expression led to an increase in transmission [Joubert
et al, 2010]. At low maternal viral loads, SNP in CCR5 (2459G and 2135T) were
associated with lower CCR5 expression in the placenta and provided some protection
against transmission [Pedersen et al, 2007].
HIV-1 Env synthesis, structure, and function
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While host genetic factors may contribute to perinatal transmission, there is also
evidence that viral factors may play a key role. Env is important in both infection and
transmission and is likely an important viral factor in perinatal transmission. An
understanding of the structure, function, and genetic diversity of Env is important in
determining its role in MTCT.
The Env glycoproteins are synthesized as a precursor glycoprotein (gp160) on the
rough endoplasmic reticulum (RER) [Hunter and Swanstrom, 1990; Freed et al, 1995].
While still on the ER, gp160 is modified by glycosylation with primarily N-linked
oligosaccharide side chains. Oligorimerization of gp160 into trimers also occurs in the
ER and is thought to facilitate trafficking to the Golgi complex. Further modification to
the oligosaccharide side chains continues as gp160 traffics through the trans-Golgi
network [Leonard 1990].
Env gp160 is proteolytically cleaved by cellular proteases at a highly conserved
K/R-X-K/RR motif in the Golgi [Freed et al, 1989]. This cleavage, which yields the
surface subunit gp120 and the transmembrane subunit gp41, is essential for viral
infectivity. Three molecules of gp120 and three molecules of gp41 form a heterotrimeric
spike. Relatively weak noncovalent interactions maintain the association between gp120
and gp41 [Zhu et al, 2003]. The spike proteins are trafficked to the plasma membrane. It
is thought that two factors contribute to the low cell surface expression and virion
incorporation of the Env proteins. First, Env is rapidly recycled via endocytosis from the
PM [Egan et al, 1996; Rowell et al, 1995]. Second, the weak interactions between gp120
and gp41 allow for shedding of gp120. The resultant low expression of the glycoproteins
is thought to contribute to immune evasion by HIV-1.
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gp120
Based on high genetic diversity, gp120 is organized into five variable regions
(V1-V5) separated by five more constant regions (C1-C5) [Starcich et al, 1986; Willey et
al, 1986]. Within these regions, the V1/V2 loop has the most diversity in length and
glycosylation. The V3 loop as well as C2, C3, and C4 have the least variation in length. It
is likely that variation in the loop length, particularly V1/V2, plays a role in immune
evasion by masking antibody binding sites [Chohan et al, 2005; Kitrinos et al, 2003;
Masciotra et al, 2002; Palmer et al, 1996; Sagar et al, 2006; Shioda et al, 1997]. The
major role of gp120 is binding of the virion to the target cell. Both the CD4 and
CCR5/CXCR4 binding sites are located within gp120. CD4 binding is determined by the
tertiary structure, where discontinuous conserved residues found in C1, C3, and C4 are
brought into proximity [Lasky et al, 1987; Kowalski et al, 1987; Olshevsky et al, 1987].
The coreceptor binding site is located in the V3 loop [Cann et al, 1992; Chesebro et al,
1991; Hwang et al, 1991; O'Brien et al, 1990; Shioda et al, 1991]. Specific mutations
within V3 facilitate the switch from CCR5 to CXCR4 usage [Fouchier et al, 1992;
Pollakis et al, 2004]. V3 also plays a role in membrane fusion [Freed et al, 1991] and
contains epitopes for neutralizing antibodies [Goudsmit et al, 1988; Matsushita et al,
1988; Palker et al, 1988; Rusche et al, 1988]. Binding to CD4 produces a large number of
conformational changes within the Env that exposes the R5/ X4 binding sites. Thus, the
unbound form of Env is able to mask the vulnerable V3 region until coreceptor binding
occurs [Chen et al, 2005].
Tertiary structure is also highly influenced by glycosylation and a number of
conserved Cysteine residues capable of forming disulfide bonds [Leonard et al, 1990].
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The gp120 is primarily modified with N-linked glycans [Allan et al, 1985] with a smaller
number of O-linked glycans [Bernstein et al, 1994]. There are approximately 20-35
potential N-glycosylation sites (PNGS) in gp120. Glycosylation plays a role in protein
folding, immune evasion, and virion binding [Montefiori et al, 1988; Li et al, 2008].
Proper tertiary structure is also dependent on the formation of disulfide bridges.
Generally, 18 Cys residues form 9 disulfide bridges. The V1 and V2 loops are separated
by two disulfide bridges and contained within a larger loop formed by another disulfide
bond. The V3 and V4 loops are also formed by disulfide bonds. Disruption of these
bonds changes Env structure and may have effects on viral properties [Gao et al, 1996;
Jobes et al, 2006].
gp41
As compared to gp120, gp41 is more conserved and arranged into three functional
domains: the extracellular domain, the transmembrane domain (TMD), and the Cterminal cytoplasmic tail (CT). The major function of the gp41 subunit is to mediate
fusion and the major fusion determinants are contained within the extracellular domain
[Bosch et al, 1989; Freed et al, 1990; Freed et al, 1992]. This domain has the N-terminus
fusion peptide that is hydrophobic as well as two hydrophobic heptad repeat regions
(HR1 and HR2) [Chan et al, 1997; Dubay et al, 1992; Lu et al, 1995; Tan et al, 1997;
Weissenham et al, 1997], a polar region, and a membrane-proximal external region
(MPER) [Munoz-Barroso et al, 1999; Salzwedel et al, 1999]. Fusion is primarily driven
by interactions between the HR regions and exposure of the fusion peptide. Upon binding
of CD4 and the coreceptor, a conformational change is induced that exposes the fusion
peptide. The exposed peptide is able to penetrate the cellular membrane of target cells,
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causing destabilization of the membrane and leading to the formation of the fusion pore
[Brasseur et al, 1990]. Next a stable six-helix bundle is formed by the interaction of 3
HR1 motifs and 3 HR2 motifs and brings the cellular and viral membranes together for
fusion to occur. To form the six-helix bundle, the HR1 motifs form a core bundle and
fold over a hydrophobic groove with the HR2 motifs [Chan et al, 1997; Weissenham et
al, 1997]. HR1 and HR2 are both targets for antiretrovirals; peptides-derived from either
heptad repeat are able to disrupt the formation of the six-helix bundle and prevent fusion
[Furuta et al, 1998; Kilby et al, 1998; Wild et al, 1994].
In addition to the fusion peptide, the MPER is also found within the extracellular
domain and is involved in promoting fusion. It has been shown to be necessary for
infectivity and fusogenicity, but the mechanism underlying the actions is unclear
[Munoz-Barroso et al, 1999; Salzwedel et al, 1999]. It is known that this region is highly
conserved and is a target of neutralizing antibodies [Cao et al, 1993; Zwick 2001].
A second domain in gp41, the TMD, anchors Env in the lipid bilayer and consists
of approximately 25 highly conserved amino acids. The TMD is necessary for Env
function and mutations within this domain have been shown to interrupt fusion [Shang et
al, 2008; Shang and Hunter, 2010; Kondo et al, 2010]. The traditional model for gp41
topology suggests that the TMD forms an alpha helix that spans the membrane one time.
With this scenario the entire CT would be contained within the virion. However, another
model suggests gp41 spans the membrane three times exposing portions of the CT to the
extracellular space [Kennedy et al, 1986; Steckbeck et al, 2010]. Current evidence favors
the single pass model, but both models may exist [Hollier and Dimmock, 2005].
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The third functional domain, the CT has multiple functions. Like other
lentiviruses HIV-1, HIV-2, and SIV have a long CT when compared to other retroviruses
[Rushlow et al, 1986; Rice et al, 1990]. The length of the CT contributes to its function as
it has been shown that truncations in the CT of SIV suppress viral replication in rhesus
macaques [Shacklett et al, 2000]. The HIV-1 CT has an impact on several properties of
Env. Viral infectivity, Env incorporation into virions, gp120 shedding, Env cell-surface
expression, gp120 and gp41 conformation, and fusion are all influenced by the CT.
Evidence that the CT plays a role in modulating gp120 conformation is that mutations in
the CT affect antibody recognition and neutralization, and truncations in the CT has been
associated with CD4 independence [Edwards et al, 2001; Edwards et al, 2002; Kalia et al,
2005].
There is also evidence that potential interactions between gp120 and gp41 affect
fusogenicity. Wang et. al. [2011] found that mutations that conferred resistance to a
fusion inhibitor targeting HR1 clustered in both gp41 and gp120. Resistance was mapped
primarily to the gp41 mutations, but the gp120 mutations were capable of enhancing
fusion and this was related to the ability to utilize CD4 and CCR5. Another study found
mutations in the gp41 ectodomain that produce an unstable gp120-gp41 complex
correlate to a decrease in fusion function [Maerz et al, 2001]. Additionally, viruses that
contain adaptive mutations in gp120 that allowed for usage of mutant forms of CCR5
were capable of fusing at a quicker rate due to reduced constraints holding gp41 [Platt et
al, 2007]. Given this evidence it is reasonable to suggest that differences in gp120 may
play a role in Env-mediated fusion.
Characteristics of HIV Env in perinatal transmission
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Several studies have highlighted the importance of Env in MTCT. The ability of
variants to use CCR5 may play a role in transmission; newly transmitted viruses from a
subtype C mother-infant-pair (MIP) MTCT cohort [Zhang et al, 2002] and a subtype A
MIP cohort [Rainwater et al, 2007] were found to use CCR5 exclusively. Even minor
variants with CCR5 phenotypes are selected for transmission in HIV-1 infected mothers
during perinatal transmission and/or are amplified after transmission [Matala et al, 2001].
Previous studies have demonstrated that, despite a complex viral population in the
mother, only viruses of a restricted subset were typically transmitted to the infant [Ahmad
et al, 1995; Contag et al, 1997; Lamers et al, 1993; Mulder-Kampinga et al, 1995;
Samleerat et al, 2008; Scarlatti et al, 1993a; Scarlatti et al, 1993b; Scarlatti et al, 1993c;
Verhofstede et al, 2003; Wolinsky et al, 1992; Zhang et al, 2002]. Controversy in the
field of pediatric HIV-1 infection has involved whether selective transmission of a
specific, homogeneous maternal viral population to the infant occurs in utero or
intrapartum; studies have failed to pinpoint a specific timing for transmission [Contag et
al, 1997; Mulder-Kampinga et al, 1995]. In some cases the transmitted strain was a minor
variant of the maternal viral pool, and was due to selective pressures against V3 (Ahmad
et al, 1995; Wolinsky et al, 1992). Despite evidence of restrictive transmission as a
characteristic of MTCT, several other groups have also reported a more random pattern
of transmission, including of multiple and/or major maternal HIV-1 genotypes from
mother to infant [Dickover et al, 2001; Lamers et al, 1994; Pasquier et al, 1998]. Mothers
acutely infected with HIV-1 that underwent near simultaneous seroconversion with their
infants transmitted a number of closely related viral variants [Hoffmann et al, 2008].
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Similarly, mothers with primary infection during pregnancy showed a random pattern of
transmission [Ceballos et al, 2008].
One source of selective pressure in perinatal transmission of HIV-1 is maternal
antibodies, which could play a role in limiting transmission of neutralization sensitive
variants. Studies have shown that nontransmitting mothers had more frequently
detectable and/or higher levels of neutralizing antibody responses than transmitting
mothers [Bongertz et al, 2002; Guevara et al, 2002; Lathey et al, 1999]. It has also been
suggested that the virus variants more resistant to neutralization are preferentially
transmitted perinatally [Scarlatti et al, 1993b]. A recent study found that variants from
infants were more resistant to neutralization by maternal plasma than the overall maternal
virus population [Rainwater et al, 2007; Wu et al, 2006]. Another study found that newly
transmitted viruses from a cohort of subtype C MIP were more resistant to neutralization
by paired maternal plasma than contemporaneous maternal plasma and more resistant to
IgG b12, but were sensitive to pooled plasma [Zhang et al, 2010b]. In contrast, others
have shown no notable differences between mother and infant viruses in sensitivity to
heterologous plasma or the antibodies 2G12 and b12. A direct association between
maternal antibodies against the V3 domain of the Env and a lower rate of transmission of
HIV-1 has been suggested by some studies [Y Devash et al, 1990; Wu et al, 2006], but
others have not found a correlation [Halsey et al, 1992; Parekh et al, 1991].
The number and location of PNGS may favor certain variants for transmission.
Several studies have shown newly transmitted viruses have shorter variable loops and
fewer PNGS [Russell et al, 2011; Wu et al, 2006; Zhang et al, 2010b); however, others do
not observe this trend [Kishko et al, 2011; Samleerat et al, 2008; Thenin et al, 2009]. A
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study of a cohort in Thailand examined the gp120 sequences from variants of CRF01_AE
clade and found that the number of PNGS was not related to transmission. However,
PNGS at positions N301 and N384 were conserved among all infant sequences and
variable among mother sequences, suggesting a potential role in transmission [Samleerat
et al, 2008]. Another study examined the V1-V5 and PNGS at N339 was found at a
higher frequency in transmitting mothers than non-transmitting mothers. They also found
that PNGS at N295 was in lower frequency in children than mothers [Baan et al, 2011].
The role of PNGS in MTCT is likely subtype specific.
Despite evidence that Env is playing a key role in MTCT, the functional role of
Env in MTCT remains controversial. Neither Env processing nor incorporation into
virions was found to predict transmission [Zhang et al, 2010b; Thenin et al, 2009]. Viral
entry, which is dependent on Env, did not differ between mother and infant variants as
measured by the response to entry inhibitors such as soluble CD4, PSC-Rantes, and
TAK779 [Rainwater et al, 2007; Thenin et al, 2009]. However, replicative fitness
mediated by V1-V5 was shown to be higher in infant viruses from chronically infected
MIP [Kong et al, 2008]. The role of the biological functions of Env, such as binding and
fusion, during MTCT still remains unclear and provides an avenue for further inquiry.
Objective
Based on the previous data that demonstrated a role for V1-V5 in the higher
replication fitness of transmitted viruses [Kong et al, 2008], our overall objective was to
determine if this region had an effect on other biological properties of Env including
fusion and binding. Our specific aims were:
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1) To determine if V1-V5 is capable of influencing fusion and if any differences
that might exist correlate to replicative fitness and predict transmission. This was
carried out by using a fluorescent resonance energy transfer (FRET) based virusto-cell fusion assay to measure the fusion efficiency in a transmitting MIP cohort
from Zambia, and determined if any differences in fusion efficiency correlated to
transmission.
2) To determine if V1-V5 is capable of influencing CD4 binding and if any
differences that might exist correlate to replicative fitness and predict
transmission. This was carried out by a virus-to-cell binding assay to measure the
binding efficiency of transmitting MIP from Zambia. We also correlated any
differences to fusion and transmission.
Our results demonstrated a positive correlation between fusion and infectivity, and there
were variations between different clones in binding and fusion efficiencies. This variation
suggests that differences in fusion and binding exist in a clone-to-clone manner, and are
likely to be influenced by the V1-V5 region of Env. However, there was no correlation
between binding and fusion activities of various Env clones and variations in fusion and
binding among clones are not predictive of their ability to transmit from mother to infant.
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Chapter 2: Virus to cell fusion of HIV-1 is influenced by envelope V1V5, but does not predict transmission.

Introduction

Despite recent efforts and successes in reducing the incidence of perinatal
transmission of HIV-1, MTCT still remains the dominant source of pediatric HIV-1
infections and presents a serious concern in countries with the highest HIV prevalence. In
these countries HIV-1 is the underlying cause of death in one-third of childhood
mortalities for children under five years of age [Bennnett and Rogers, 1991; UNAIDS,
2008]. In the absence of ART, perinatal transmission rates remain between 30-45% in
many developing countries [Bulterys et al, 1998; Lathey et al, 1999]. In sub-Saharan
Africa, where HIV-1 infection is epidemic and access to ART is limited, perinatal
transmission remains a major pediatric concern [Cooper et al, 2002]. Since prevention of
MTCT remains a key goal in the global fight against HIV/AIDS, a better understanding
of the possible mechanisms underlying MTCT, including functional properties of
transmitted viruses, remains critical.
Many of the studies investigating transmitted viruses from mother-infant-pair
(MIP) cohorts are contradictory. In general, restrictive transmission of a small viral
subset appears to be a hallmark of MTCT in mothers chronically infected with HIV-1. In
some cases where infection in the infant was established by a minor variant of the
maternal viral pool; selection for the minor variant is attributable to pressures against V3
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[Ahmad et al, 1995; Wolinsky et al, 1992]. Coreceptor usage, a function of V3, may play
a role in transmission. In both a subtype C MIP cohort [Zhang et al, 2002] and a subtype
A MIP cohort [Rainwater et al, 2007] newly transmitted viruses were found to use CCR5
exclusively. Others have observed selection for minor variants with CCR5 phenotypes in
HIV-1 infected mothers during perinatal transmission and/or amplification of CCR5
using variants after transmission [Matala et al, 2001]. This data suggests a role for Env in
determining perinatal transmission and that there is functional difference between the
Env of transmitted and non-transmitted viruses. Neutralization sensitivity likely plays a
role in transmission. Multiple studies have shown a relationship between low levels of
neutralizing antibody response in mothers [Bongertz et al, 2002; Guevara et al, 2002;
Lathey et al, 1999] and neutralization resistance [Scarlatti et al, 1993; Rainwater et al
2007; Wu et al, 2006] and transmission. Some studies have proposed a direct association
between maternal antibodies against the V3 domain of the Env and a lower rate of
transmission of HIV-1 [Y Devash et al, 1990].
The number and location of potential N-glycosylation sites (PNGS) in Env may
also be a target of selection for certain variants during transmission. Newly transmitted
viruses with shorter variable loops and fewer PNGS have been observed in many studies
[Russell et al, 2011; Wu et al, 2006; Zhang et al, 2010]. PNGS at positions N301, N384
[Samleerat et al, 2008] and N339 [Baan et al, 2011] are all associated with transmitted
viruses. There also appears to be selection against PNGS at N295 [Baan et al, 2011].
Sequential evidence suggests Env is playing a key role in MTCT; however, the
functional role of Env in MTCT remains unknown. Neither Env processing nor
incorporation into virions is predictive of transmission [Zhang et al, 2010; Thenin et al,
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2009]. Env mediated-viral entry, measured by the response to entry inhibitors such as
soluble CD4, PSC-Rantes, and TAK779, did not differ between transmitted and
nontransmitted variants [Rainwater et al, 2007; Thenin et al, 2009]. However, our
previous studies observed replicative fitness mediated by V1-V5 to be higher in infant
viruses from chronically infected MIP [Kong et al, 2008]. Based on the data available we
decided to further examine the functional role of Env during viral entry into target cells
as a potential determinant of transmissibility.
Entry of virus into target cells is determined mainly by Env function. Entry has
two distinct stages, binding and fusion. While the fusion domain is found within gp41,
fusion is subsequent to binding and may be influenced by both the structure and function
of gp120. Thus, we hypothesized that gp120 may also be playing a role in influencing
fusion, in addition to binding, which could contribute to the fitness advantage found in
transmitted viruses.

Materials and Methods

Patient information
The subjects of this study were selected from a Zambian perinatal
transmission cohort followed for HIV-1 infection. We chose five MIP (2669, 2617, 1084,
1449, and 2873) for our current study. All the pairs chosen represented chronically
infected mothers, mothers infected at delivery likely via sexual transmission, which
transmitted to their infants. Venous blood was obtained from the mothers before delivery
and HIV-1 serological status was determined by two rapid assays, Capillus (Cambridge
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Biotech, Ireland) and Determine (Abbott laboratories), and confirmed by
immunofluorescence assay. All mothers were HIV-1 positive at delivery and this was
subsequently defined as baseline for mothers.
Children from these MIPs represented both rapid (2669, 2617, 1449, 2873) and
slow (1084) progressors as determined by clinical outcome and survival. Rapid
progressors died within the first year of life due to HIV-related complications, while slow
progressors were followed for more than four years and remained clinically
asymptomatic. All children remained anti-retroviral naïve throughout the study. Venous
blood was also obtained from the infants within 24 hours of birth and follow-up was
maintained at 2, 4, and 6/8 months and at regular intervals through 48 months (for slow
progressors). HIV-1 infection in the infants was detected by sequential viral isolation
from the infants' peripheral blood mononuclear cells (PBMC), as previously described
[Zhang et al, 2005] and by PCR of the HIV-1 provirus env gene from genomic DNA.
HIV-1 isolation was unsuccessful from all samples and all infants were PCR negative at
birth, suggesting either intrapartum or postpartum transmission. HIV-1 env sequences
were amplified from infant PBMC at different postpartum time points. Due to the limited
sample volume, viral isolation was prioritized over PCR when required (e.g., infant 1084,
viral isolation was positive by 4 month and the first PCR was performed 6 month after
birth) (Table 1). Mother samples were defined as baseline at the time of delivery. Infant
samples were collected at the first postpartum, HIV-1 PCR positive time point.
Viral Isolation
A portion of the env gene from V1–V5 was amplified by PCR, cloned, and
sequenced in order to characterize Env genetic diversification and evolution. Sequence
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analysis from each MIP showed the mother and infant viruses were epidemiologically
linked. All cases were subtype C based on Env, except for 1449 (subtype A/C
recombinant). All viruses were also shown to be CCR5 tropic [Zhang et al, 2005].
Between four and six representative functional and fusion-positive Env clones from each
MIP baseline were used for further analysis (Table 1). The V1-V5 fragments were
ultimately cloned into a proviral expression vector, pNL4-3 A/S/AV, resulting in
infectious molecular clone plasmids that express Env as a chimeric protein with the
patient's Env V1-V5 region and HIV-1 strain NL4.3 (Fig.1)

Cell cultures
293T and TZM-bl (NIH AIDS Research and Reference Reagent Program catalog
no. 8129) cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM) with
10% fetal bovine serum (FBS, Gibco) and 100ug/ml penicillin-streptomycin (Invitrogen).
SupT1-CCR5 (from Dr. James Hoxie, Emory University) were maintained in RPMI with
10% FBS, 100ug/ml penicillin-streptomycin, and 300ng/ml puromycin. All cells were
grown at 37ºC with 5% CO2.

Proviral expression constructs
The V1-V5 region of the env gene was amplified by nested PCR from uncultured
patient PBMC using the Gentra Kit (Purgene), cloned into the pGEM-T Easy vector and
sequenced as described [Zhang et al, 2006]. The Env V1-V5 region from selected clones
was amplified from the pGEM-T Easy vector and subcloned into the pSP72 NLA/S/Av
shuttle vector. The chimeric Env expression construct containing patient-derived Env V1-
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V5 region was generated by substituting the EcoRI-XhoI region of pSP72A/S/Av with
the corresponding region of pSRH NL A/S/Av to screen for biological function as
described [Zhang et al, 2010]. Functional envelope constructs were transferred into a
proviral expression vector, pNL4-3 A/S/Av, by substituting EcoRI-XhoI region of pSRH
NL A/S/Av with the corresponding region of pNL4-3 A/S/Av, resulting in infectious
molecular clone plasmids with an NL4-3 backbone.

Viral Production
Viruses bearing patient-derived Env V1-V5 and BlaM-Vpr were produced by
calcium phosphate transfection of 293T cells. Approximately 2.0x106 293T cells were
transfected with 9ug of proviral construct, 3.0ug of pMM310 (BlaM-Vpr) (NIH AIDS
Research and Reference Reagent Program catalog no. 11444), and 1.5ug of pAdVantage
(from Dr. Gregory Melikyan, Emory University) in a 10cm dish. At minimum three
dishes were used for each proviral construct. After 48 hours post-transfection, the
infectious virus was harvested, centrifuged to clarify debris, and pooled. The viral stocks
were concentrated by ultracentrifugation using the SW-41 Ti rotor (Beckman Coulter) or
the SW 32 Ti rotor (Beckman Coulter) at 20,000rpm for 2 hours at 4ºC. The viral pellet
was resuspended at a 30x-40x final concentration and stored at -80ºC. The amount of
HIV-1 in the viral stocks was measured using the HIV-1 p24 ELISA kit (PerkinElmer
Life Sciences, Inc.). Samples were diluted at 1:500,000 using DMEM culture media,
mixed with the lysis buffer contained in the kit, added to the antibody-coated plates, and
incubated at 4ºC overnight. All other steps were performed according the manufacturer
protocol. Viral titer was confirmed measuring the p24 levels by western blot analysis.
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Protein incorporation in virions
Western blot analysis was carried out to determine the incorporation of p24,
gp120, and BlaM-vpr into virions. Viral stocks were normalized by p24 (as described
above) and lysed for SDS-PAGE. Viral proteins were separated on a 4-20% agarose
gradient gel, transferred to a nitrocellulose membrane and then analyzed by Western blot.
A polyclonal goat anti-HIV-1 gp120 antibody (Thermo Scientific Pierce) was used to
detect gp120, polyclonal rabbit anti- HIV-1 Vpr (1-46) antibody (NIH AIDS Research
and Reference Reagent Program catalog no. 3951) to detect vpr and BlaM-vpr, and
polyclonal rabbit anti-HIV-1SF2 p24 antibody (NIH AIDS Research and Reference
Reagent Program catalog no. 4250) to detect p24. Protein quantification was performed
using the Odyssey Infrared Imager (Li-Cor).

Fusion
Viruses containing the patient Env V1-V5 and BlaM-Vpr were used to measure
virus-to-cell fusion in a fluorescent resonance energy transfer (FRET) based assay as
previously described [Cavrois et al, 2002]. One day prior to infection SupT1-CCR5 cells
were removed from puromycin selection. On the next day, 250,000 SupT1-CCR5 cells
were transferred to each well of a 96-well V-bottom plate. Based on p24 ELISA data,
50ng of p24 of each virus was added to the cells in a total volume of 100ul. Cells were
incubated with virus for 2hrs at 37ºC with 5% CO2. After incubation the virus was
removed from the cells and fusion was quantitated based on beta-lactamase activity using
the GeneBLAzer in vivo Detection Kits (Invitrogen catalog no. 12578-134). A loading
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solution containing a 1:4 ratio of CCF2-Am substrate, resuspended in DMSO (kit
solution A), to Pluronic®-F127 surfactant in DMSO and acetic acid (kit solution B) in
CO2-Independent media, was added to the cells and incubated for 1hr at room
temperature in the dark. This solution was removed and the cells were washed with the
CO2 -Independent media. A developing solution containing 2.5mM probenecid and 10%
FBS in CO2 -Independent media was added to the infected cells, and then allowed to
incubate overnight (16hrs) at room temperature in the dark. After overnight incubation
the developing solution was removed from the cells, the cells were then washed, and
fixed in 1.2% paraformaldehyde for flow cytometry analysis.
Upon virion fusion to the plasmid membrane, the BlaM-Vpr protein can be
internalized into the cell. Cells with BlaM activity will demonstrate a shift in the CCF2AM FRET pattern from green to blue due to cleavage of CCF2-AM and are considered
fusion positive. The change in emission patterns was observed by flow cytometry using a
DxP 10 modified BDFacScan (Cytek Development Inc). CCF2-AM was excited at
407nm. Green emission was detected with the 545/30 filter and blue emission was
detected using a 450/50 filter. Fusion was quantified by the percentage of blue
fluorescing cells.

Infectivity
Viral infectivity was measured by the tissue culture dose for 50% infectivity
(TCID50) on TZM-bl cells. One day prior to infection, TZM-bl cells were plated at a
density of 1.5 X104 cells/100ul/well in a 96-well plate. Viral stocks were diluted 10-30fold in culture media containing 40ug/ml DEAE-Dextran. Four fold serial dilutions (4-1-4-
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) were made from this stock and transferred to the cells. Each virus dilution was done in

quadruplicate. After 48 hours the virus was removed from the cells, the cells were then
fixed and stained for beta-galactosidase activity. Viral titer was calculated as TCID50/ml
using the Reed-Muench method.

Results

V1-V5 of Env is capable of influencing fusion.
Chimeric viruses bearing patient-derived Env V1-V5 in a Subtype B, NL4.3
backbone were used to assess the fusion capabilities of 5 MIPs. We used a FRET-based
virus to cell fusion assay in order to quantify the percentage of cells that have undergone
fusion. Infectious viruses were produced by a triple transfection of 293T cells with the
proviral plasmid, the pMM310 (BlaM-Vpr) plasmid, and the pADVantage plasmid (used
to boost translation). Virions produced by this method will incorporate the chimeric Env
and package the BlaM-Vpr fusion protein.
We used the CCR5-tropic AYDA strain as a positive control for dye loading and
BlaM activity. The AYDA V1-V5 was cloned into the NL4.3 backbone using the same
strategy as the patient-derived Env variants. All fusion was plotted relative to AYDA as
the reference clone. The AYDA clone consistently produced a strong positive signal with
approximately 70% of the cells with a shift from green to blue fluorescence. In all MIPs
tested clone-to-clone variation in fusion activities was observed (Fig. 2).
With MIPs 2617, 1449, 2873 fusion between patient-derived clones with target
cells varied from 12.5-58.3%, 23.6-64.9%, and 27.9-48.7%, respectively. Relative fusion
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activities of clones from MIP 2617 ranged from 43.7-104.8%, with clone M3 having the
highest fusion and clone i3 the lowest (i indicates infant clones and M denotes mother
clones in all designations). For MIP 1449 the mother clones had both the highest (M2)
and lowest fusion (M3). Relative fusion activities of clones from MIP 1449 ranged from
28.6-81.5%. For MIP 2873, relative fusion was between 39.4-68.9%. Once again with
this pair the mother clones had both the highest (M1) and lowest fusion (M3), but fusion
was very similar for all viral variants from this pair. For MIP 2669 and 1084, the
differences in fusion were much more dramatic. Clone i1 from 2669 fused at least 2.5
times greater than any other clone and 22 times greater than the weakest clone (mother
M4). The M4 clone fused 4.3 times less than any other clone. Overall, fusion activities of
clones from MIP 2669 varied from 59.4-95.5%. With MIP 1084 2 mother clones (M3 and
M4) have high fusion activities, while all other clones have much weaker fusion activities
compared to these clones and most of the other MIPs. The M3 and M4 fused 102.6% and
115.6% relative to AYDA while all other clones fused less than 5%. Clone i3 fused less
than 1%.
There was also wide clonal variation in fusion in viruses isolated from the same
patient (Fig. 2). With 1084M fusion was 100 times greater with clones M3 and M4
compared to M1. 1084i fusion varied by 8-fold amongst variants. In 2669M fusion varied
over 9-fold between the lowest (M4) and highest (M2) clones. All other patients had a 25-fold variation with clones from the same patient.
In order to rule out any differences in fusion caused by BlaM-Vpr incorporation
into virions, western blots were performed on all viral preparations. The amount of
BlaM-Vpr was measured using an antibody to vpr. We did not see a difference in BlaM-
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vpr incorporation between any of the MIP (data not shown). Any differences in fusion are
thus attributable to Env. Since all clones also contained the same gp41 fusion domain
from NL4.3, therefore the dramatic differences we see in fusion of these MIP are due to
their differences in the V1-V5 region.

Fusion activities cannot predict transmission.
Overall, there was no difference in fusion activities that can differentiate between
the transmitted clones and non-transmitted viral clones. None of the MIP clones,
individually or as a group, displayed a pattern in fusion capabilities that could predict
whether they were derived from the mothers or from the infants (Fig 3). For MIP 2617
and 1084, the mother viruses appeared to have a slight advantage in fusion over the infant
viruses, but this was not significant. For MIP 2669, infant viruses have slightly higher
fusion activities over mother viruses, but this is also non-significant. MIP 1449 showed
similar fusion in both mother and infant viruses (Fig 3a). Overall, the mother viruses as a
group had a slight advantage in fusion over infant viruses (Fig 3b). However, this
advantage is not significant (p 0.097). In summary, wide clone-to-clone variation among
clones from all patients, but there is no distinct pattern to fusion activities that are
characteristic of the transmitted infant versus the non-transmitted maternal clones.

Fusion correlates with infectivity.
We then tested the ability of the various maternal and infant viral clones to infect
target cells. Viral infectivity was measured by titration on TZM-bl cells. Infectivity was
found not to be predictive of transmission. Infectivity of the viral clones from mother and
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infant pairs varied within a transmission pair, and among all the clones obtained from the
cohort (Fig. 4). In general, clones within a pair varied up to 15 times in terms of
infectivity. For example, for MIP 2669 clone i1 has much higher infectivity than the other
clones, with infectivity 40 times greater than that of the least infectious clone. MIP 1084
demonstrated a more variable pattern of infectivity. Once again, infectivity of 1084 viral
clones M3 and M4 were much higher than the other clones. When excluding these two
viral clones, other 1084 isolates were more similar to each other (varied by less than 10
times) and were similar to other viral clones obtained from other MIPs. Overall, fusion
activity correlates to infectivity (Table 2). For pairs 2669, 1084, and 2873 fusion
correlated strongly with infectivity as measured by viral titer, with R2 values of 0.899,
0.992, and 0.885, respectively. MIP 1449 showed a slightly lower correlation with an R2
of 0.764. MIP 2617 was the only pair that did not show a strong correlation between
infectivity and fusion (R2 0.204). This pair demonstrated much less variation in fusion
than other pairs, but still displayed variation in infectivity that was similar to other MIPs.

Incorporation of Env into virions does not determine fusogenicity.
In order to determine whether fusogenicity and infectivity of the various viral
clones were affected by the amount of Env gp120 incorporated into the virion, we
determined and compared the gp120 incorporation into each viral clone by western blot.
Equal amounts of virus was lysed and loaded onto a gradient gel based on viral titer
determined by p24 ELISA. Both p24 and gp120 were detected. Env incorporation was
based on the amount of Env detected after normalizing to the amount of input viruses
based on the p24 signal (Fig 5). Env incorporation did not significantly differ between the
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mother and infant viral clones from the MIPs except 2873. Although infant viruses from
MIP 2669 appear to have a higher Env incorporation, this trend was not significant (t-test,
p 0.113). For MIP 2873 the mother viruses incorporated slightly more Env than infant
viruses (t-test, p 0.025). For MIP 1084 clone M4 also incorporated more Env than the
other clones. However, there is no correlation between fusion activities and the amount of
Env incorporated by different viral clones (Table 3). Only clones from MIP 1084 showed
some correlation between fusion and Env incorporation (R 0.826, R2 0.682). For MIP
1084 clones M3 and M4 showed a dramatic increase in fusion compared to the other
clones. There was correlation observed between incorporation and fusion for these two
clones, the higher levels of Env incorporation may have resulted in their higher fusion
activities. Whereas for the variants from 1084 that have similar fusion activities there
appeared to be a slight inverse relationship between fusion and incorporation (R -0.807),
but this correlation is not very strong (R2 0.651). This is likely due to clone i3 which had
very low fusion despite incorporating a relatively high amount of Env, suggesting there
may be some qualitative difference among different Env in their ability to mediate fusion
and infection. Such differences need to be further investigated.

Discussion

Our previous study showed that V1-V5 of env is capable of influencing
replicative fitness of viral variants from MIP and the fitness is predictive of transmission
[Kong et al, 2008]. However, envelope mediated fusion fails to explain a higher
replicative fitness in infant viruses and does not predict transmission. Previously, we had
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also observed that Env synthesis and processing, viral infectivity, replication kinetics, and
Env incorporation into virions failed to predict transmission [Zhang et al, 2010]. The
fusion results agree with the other functional data that suggests Env functions measured
do not predict transmission and viral replicative fitness. It is likely that at least some of
the discordance between replicative fitness and the other functional properties of Env that
have been measured from clones from these MIP can be attributed to differences in viral
preparations. The fitness assay represents a more heterogeneous viral population because
the virus used was prepared by allowing for a recombination of the env as a PCR product
and an env deficient backbone. The other properties were all measured with full-length
proviral clones and represent a homogeneous viral population. The fitness assay also used
a long incubation time that measured multiple rounds of replication that likely included
recombination events between the mother and infant clones. Of the biological properties
of Env that were measured in this study, only infectivity measures multiple rounds of
replication. However, the incubation time for fitness is over twice as long as infectivity. It
is likely that the very early infection events measured in the current study are different
from later events and explains, at least in part, why fitness and fusion data do not
correlate.
This study demonstrated a correlation between the fusion activities and
infectivities of the viral clones that was expected. Fusion is a key part of the entry process
and initiates infection. We would expect that viral variants with higher fusion activities
are more capable of entering target cells and this is reflected in infectivity measured in
the first few rounds of replication. We did not see a correlation between fusion activities
of viral clones and the amount of Env incorporated into virions of the clones. The lack of
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a correlation between these two Env properties of the viral clones suggests that there are
some qualitative differences in Env from these clones.
This study does show that V1-V5 of env is capable of influencing fusion, even
though all variants contained the same fusion domain (gp41). This is possibly due to the
stability of the gp120-gp41 complex. Recent studies have shown potential interactions
between gp120 and gp41 affect fusogenicity. Mutations in the gp41 ectodomain that
produce an unstable gp120-gp41 complex correlate to a decrease in fusion function
[Maerz et al, 2001]. This study also suggests that there are some biological differences
found in the Env variants isolated within a patient. Within a patient (2669M) high and
low fusing clones vary by seven times and this is not due to the amount of Env
incorporated into the virions. Thus, fusion in general is not simply determined by the
amount of Env expressed on the virion. However, there are exceptions. For example, for
variants 1084 M3 and 1084 M4 the levels of Env incorporation are contributing to the
dramatically higher fusion and even for these clones Env incorporation alone cannot
account for the differences in fusion. It is possible that primary sequence differences
between different env clones may influence their fusion activities. However, upon
preliminary analysis there does not appear to be any common mutations, insertions, or
deletions that are characteristics of the Env with either high or low fusion activities. It is
likely that the Env conformation may play an important role in influencing fusion. Postsecondary modifications, such as glycosylation, that effect protein folding and stability
are potential determinants of fusogenicity. Additionally, viruses that contain adaptive
mutations in gp120 that allowed for usage of mutant forms of CCR5 were capable of
rapid fusion kinetics due to a reduced constraint on gp41 in mediating fusion [Platt et al,
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2007]. Finally mutations that accumulated in gp120 in response to fusion inhibitors were
capable of enhancing fusion and this was related to the ability of these mutations to
utilize both CD4 and CCR5 [Wang et al, 2011]. Env stability and CD4/CCR5 utilization
should be further characterized in our clones to better understand the fusion properties
and whether higher fusion activities correlate to their ability to use other coreceptors in
addition to CCR5.
In summary, our data suggests that the gp120-gp41 interaction is important in
determining the functional properties of Env including fusion, but fusion is not predictive
of perinatal transmission. However, it is likely that the Env structure and its stability may
play key roles during viral fusion and ultimately mediating entry into target cells.
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Figure Legend
Fig. 1. Organization of proviral plasmids. The V1-V5 region from each viral isolate of
the MIPs was cloned into a NL4-3 backbone to produce an infectious molecular clone
plasmid. Env is expressed as a chimeric protein.
Fig. 2. Relative fusion. Fusion was examined using a FRET-based assay. Virions are
produced by transfection in 293T cells and incorporate the chimeric Env protein with V1V5 from the patients and package a BlaM-Vpr fusion protein. Infections are done in
SupT1-CCR5 cells and then cells are loaded with CCF2-AM and express a green
fluorescence. Upon fusion, the BlaM-Vpr protein enters the cell and cleaves CCF2-AM
producing a blue fluorescence. Fusion is quantified as the total percentage of blue cells.
For each pair AYDA is used as a positive control and relative fusion is calculated as a
percentage of the AYDA signal. Each graph represents at least four experiments, except
2873 which only represents two
Fig 3. Fusion of infant versus mother viruses. A. Comparison of infant (◊) and mother
(o) variants with patient-derived V1-V5 for each transmission pair. B. Comparison of all
infant (◊) and mother (o) variants. The p value was calculated using a two-tailed Student
paired t-test and is shown.
Fig. 4. Infectivity of MIP-derived viruses. Viral stocks were titrated on TZM-bl cells
and infectivity was measured as the TCID50/ml. Four fold serial dilutions were made
from viral stocks and transferred to the cells. After 48 hours the virus is removed and
cells are fixed and stained for beta-galactosidase activity. The TCID50/ml was measured
using the Reed-Muench method.
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Fig. 5. Env incorporation into virions. Western blot analysis was done to determine the
incorporation of gp120 into virions. Viral stocks were normalized by p24. Viral proteins
were separated on a 4-20% agarose gradient gel, transferred to a nitrocellulose membrane
and analyzed by Western blot. A polyclonal goat anti-HIV-1 gp120 antibody (Thermo
Scientific Pierce) was used to detect gp120 and polyclonal rabbit anti-HIV-1SF2 p24
antibody (NIH AIDS Research and Reference Reagent Program catalog no. 4250) to
detect p24. Protein quantification was performed using the Odyssey Infrared Imager (LiCor). Env incorporation into virions was calculated as the gp120/p24 ratio; the NL4-3
ratio was set at 1 and all values calculated relative to this value.
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Table 1. Summary of mother and infant transmission pairs.
Ti me point
analyzeda

Number of
clones

Co-receptor

Disease
progression

Cause of
death

Infant

2 mo.

3

CCR5

Rapid

Bronchitis

Mother

Delivery

3

CCR5

Infant

2 mo.

3

CCR5

Rapid

Pyrexia

Mother

Delivery

3

CCR5

Infant

6 mo.

3

CCR5

Slow

Survived

Mother

Delivery

3

CCR5

Infant

2 mo.

2

CCR5

Rapid

Pneumonia

Mother

Delivery

2

CCR5

Infant

2 mo.

3

CCR5

Rapid

Tuberculosis

Mother

Delivery

3

CCR5

MIP
2669

2617

1084

1449

2873

a Months

after birth.
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Table 2. Correlation between infectivity and
fusion.

MIP

R value

R2

2669

0.948

0.899

2617

0.452

0.204

1084

0.996

0.992

1449

0.874

0.764

2873

0.941

0.885
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Table 3. Correlation between Env incorporation and
fusion.

MIP

R2

R value

2669

0.404

0.164

2617

0.429

0.184

1084

0.826

0.682

*i1, i2, i3, M1

-0.807

0.651

*M3, M4

1

1

1449

0.587

0.344

2873

0.578

0.335
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Chapter 3: Virus to cell binding of HIV-1 is influenced by envelope V1V5, but does not predict transmission.

Introduction

Viral entry into target cells is a multi-step process that is initiated by the binding
of virions to the viral receptor, CD4. Upon CD4 engagement, a conformational change is
induced in Env that exposes the V3 loop and the coreceptor binding site. Engagement of
the coreceptor, CCR5 or CXCR4, another conformational change occurs that exposes the
fusion domain. Fusion then occurs subsequent to binding. Both binding and fusion are the
primary functions of Env.
The major role of gp120 is in binding the virion to the target cell. There are
multiple CD4 binding sites within gp120 that are brought into the proper conformation by
the gp120 tertiary structure to allow for CD4 binding [Lasky et al, 1987; Kowalski et al,
1987; Olshevsky et al, 1987]. The coreceptor, both CCR5 and CXCR4, binding site is
located in the V3 loop, but other domains within the V1-V5 region can also be involved
to strengthen or weaken binding [Cann et al, 1992; Chesebro et al, 1991; Hwang et al,
1991; O'Brien et al, 1990; Shioda et al, 1991]. Coreceptor usage is determined by the
gp120 sequence; specific mutations within V3 facilitate the switch from CCR5 (R5) to
CXCR4 (X4) usage [Fouchier et al, 1992; Pollakis et al, 2004]. V3 also plays a role in
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membrane fusion [Freed et al, 1991] and contains epitopes for neutralizing antibodies
[Goudsmit et al, 1988; Palker et al, 1988; Rusche et al, 1988].
As the main function of gp120 of env is viral binding, we sought to compare the
binding efficiencies of the V1-V5 region of the gp120derived from viruses isolated from
subtype C infected mother-infant-pairs (MIP) and determine whether their binding
abilities can predict transmitted viruses during perinatal transmission, and if it is
contributing to higher replicative fitness in infant viruses from our cohort. We also sought
to examine the relationship between binding and fusion as we examined fusion using the
FRET-based assay (previously described) in parallel with binding.
We examined binding in three of the MIPs (2669, 2617, and 1084) described
previously. All these pairs represent chronically infected mothers with their infants
classified as rapid (2617, 2669) versus slow (1084) progressors. It is also important to
note that all the viral variants examined for binding use CCR5 for entry. We sought to
examine binding using the EGFP/DsRed2 expressing viruses that were used for the
growth competition assay [Kong et al, 2008]. We also used viruses without any marker to
examine binding. In addition, we decided to examine fusion and binding in parallel and
used the SupT1-CCR5 cell line and the BlaM-Vpr containing viruses.

Materials and Methods

Patient information
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The three mother infant pairs (2617, 2669, 1084) in this study have been
described previously [Zhang et al, 2006]. All mothers were HIV-1 positive at delivery,
asymptomatic, and not undergoing ART. The infants were all breast-fed and drug naïve
as well. Mother samples were defined as baseline at the time of delivery. Infant samples
were collected at the first postpartum, HIV-1 PCR positive time point.

Cell cultures
293T and TZM-bl (NIH AIDS Research and Reference Reagent Program catalog
no. 8129) cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM) with
10% fetal bovine serum (FBS, Gibco) and 100ug/ml penicillin-streptomycin (Invitrogen).
SupT1-CCR5 (from Dr. James Hoxie, Emory University) were maintained in RPMI with
10% FBS, 100ug/ml penicillin-streptomycin (pen/strep), and 300ng/ml puromycin. U87
(NIH AIDS Research and Reference Reagent Program catalog no. 2188) cells were
maintained in DMEM with 10% FBS and 100ug/ml pen/strep. U87.CD4.CCR5 cells
(from Dr. Lee Ratner, Washington University) were maintained in DMEM with 10%
FBS, 4mM Glutamine, 1mM Sodium Pyruvate, 200 µg/ml G418, and 1 µg/ml
Puromycin. All cells were grown at 37ºC with 5% CO2.

Proviral expression constructs
The V1-V5 region of env gene was amplified by nested PCR from uncultured
patient PBMC using the Gentra Kit (Purgene), cloned into the pGEM-T Easy vector and
sequenced as described [Zhang et al, 2006]. Generation of infectious molecular clone
plasmids with MIP-derived Env V1-V5 and an NL4-3 backbone was described
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previously. The chimeric env region was also substituted into the 4-3 EGFP/DsRed2
using EcoRI and BamHI, resulting in molecular clone plasmids that express either EGFP
or DsRed2.

Viral Production
Viruses bearing patient-derived Env V1-V5 and BlaM-Vpr were produced as
described previously. (NIH Awith or without EGFP/DsRed2 were produced by
transfection of 293T cells using the FuGENE 6 (Roche). 1.5x105 293T cells were
transfected with 1.5ug of proviral DNA and 5ul of FuGENE in 1 well of a 6-well plate.
The total volume in each well was 2ml and multiple wells were combined for each virus.
Viral stocks were filtered through 0.45um filters and stored at -80ºC. All viral stocks
were measured using a HIV-1 p24 ELISA kit (PerkinElmer Life Sciences, Inc.). Samples
were diluted 1:500,000 using DMEM culture media, mixed with the lysis buffer
contained in the kit, added to the antibody-coated plates, and placed at 4ºC overnight. All
other steps were performed according the manufacturer protocol.

Virus-to-cell Binding
Binding of viruses containing the patient Env V1-V5 with or without
EGFP/DsRed2 was done in U87-derived cells. One day prior to the assay U87 and
U87.CD4.CCR5 cells were plated at 4x105/well in 1 well of a 6-well plate. The next day
40ng of p24 of each virus was added to the cells and incubated for 1hr at 4ºC. Cells were
vigorously washed with PBS. A lysis buffer containing 0.5% NP40 was added to the
plates and cells were collected in Eppendorf tubes. Cultures were lysed at 4ºC for 1hr
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with constant agitation. Lysates were clarified by centrifuging at 10,000xg for 10min and
assayed for bound p24 by p24 ELISA as described above. Relative binding is determined
using the U87 cell line to measure background signal (non-specific binding) and
expressed as a fold increase over this level.
Binding of viruses containing the patient Env V1-V5 and BlaM-Vpr was carried
out with SupT1-CCR5 cells. One day prior to infection SupT1-CCR5 cells were removed
from puromycin selection. On the next day, 250,000 SupT1-CCR5 cells were transferred
to each well of a 96-well V-bottom plate. Based on p24 ELISA data, 50ng of p24 of each
virus was added to the cells in a total volume of 100ul of CO2-independent media. Cells
were incubated with virus for 2hrs at 4⁰ C. After 2hrs cells were washed with PBS to
remove unbound virus. Cells were lysed in a solution containing 0.5% Triton X-100 for 1
hr at 4⁰ C. Lysates were clarified by centrifugation at 10,000xg for 10min. Bound p24 in
the lysate was measured by p24 ELISA as described above. Percent binding was
calculated as the bound p24/input p24x100.

Virus-to-cell Fusion
Viruses containing the patient Env V1-V5 and BlaM-Vpr were used to measure
virus-to-cell fusion in a fluorescent resonance energy transfer (FRET) based assay as
previously described [Cavrois et al, 2002]. Virus-to-cell fusion was performed as
described previously using SupT1-CCR5 cells.

Results
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Env V1-V5 influences viral binding in adherent cells
Initially, we sought to determine virus-to-cell binding in adherent cell lines using
the U87 and U87.CD4.CCR5 cell lines. To determine binding we incubated U87 and
U87.CD4.CCR5 cells with viral preps at 4ºC to prevent fusion. Next we attempted to
wash away any unbound virus, collected and lysed the cells, and assayed bound p24
using an ELISA. The U87 cell line was used to determine the background signal of the
assay (a combination of unbound virus and non-specific binding). Relative binding was
then measured as fold-increase over the background. First, we tested binding using MIP
1084 and viruses with either an EGFP (infants) or DsRed2 (mothers) fluorescent tag. We
saw a small clone-to-clone variation in viral isolates from MIP 1084 (Figure 1a). Clones
i3, M2, and M3 all showed similar levels of relative binding at 1.92, 1.98, and 1.72,
respectively. Clone i1 showed a slightly elevated binding at 2.60. However, when we
attempted to test relative binding in non-tagged virus this pattern did not remain
consistent. A representative experiment is shown in Figure 2a. All clones in this
experiment had similar levels of binding, ranging from 1.42-2.29. In contrast to the
previous experiment, clone i1 showed a lower binding (1.76) than other infant clones, but
it was still higher than the mother clones (M1 1.44, M3 1.42).

Binding does not predict transmission in adherent cells.
Overall, the relative binding is not predictive of transmission. When using the
non-tagged viral preparations; we observed a trend towards higher binding in the infants
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(p=0.056, Fig. 2b). However, we did not observe the same trend using the fluorescentlytagged viral stock (p=0.303, Fig. 1b). Ultimately we were unable to resolve these
discrepancies. While there might be a trend towards higher binding in infant viruses; the
role of binding as an indicator of transmission remains unclear.

Env V1-V5 influences viral binding in suspension cells
Next, we observed fusion in suspension cells. We used the same SupT1-CCR5
that we had previously used to determine fusion. As we assayed for both fusion and
binding concurrently in this set of experiments, we used the viral stocks with the BlaM
marker. To determine binding we incubated SupT1-CCR5 cells with viral preps at 4ºC,
washed away any unbound virus, lysed the cells, and assayed bound p24 using an ELISA.
In this assay binding is measured as the percentage of bound virus and calculated as
bound virus/input virus x 100. We tested three MIPs (2669, 2617, 1084). Overall, we saw
very little binding in this assay (Fig. 3a-c). The highest percent binding observed was
3.34% (2669 M4). A majority of the clones bound less than 1% of the initial virus
available. In the case of 1084, less than 0.1% of viruses were capable of binding. In the
case of MIPs 2669 and 2617, differences in binding between clones could be quite
significant. For 2669, binding varied up to 10-fold between the highest (M2 3.33%, M4
3.34%) and lowest (i3 0.30%) clones. In 2617 binding varied over 30-fold between M5
(2.50%) and i1 (0.075%). MIP 1084 showed much less variation in binding among the
clones, varying less than 2% between all clones.

Binding does not correlate with fusion and does not predict transmission
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We examined binding and fusion concurrently in the SupT1-CCR5 cells. Unlike
with the binding assay, cells were incubated with virus at 37ºC to allow binding to
progress through fusion and entry to be completed. Fusion was assayed as described
above. We see a difference in fusion among viral variants from each MIP (Fig. 3d-f).
However, this difference in fusion does not correlate to the differences in binding (Table
1). In fact, both MIP 2617 and 1084 showed an inverse relationship. This relationship is
not significant as the correlation was extremely weak at R= -0.192 and R= -0.027 for
MIP 2617 and 1084 respectively. MIP 2669 showed a positive and stronger correlation at
R= 0.424, but again this is not significant.
Neither binding nor fusion were capable of predicting transmission in any of the
MIPs we assayed (Fig. 4). Despite dramatic differences among clones in binding and
fusion, there was no pattern between mother and infant clones that could distinguish them
from each other (Fig. 4a). MIP 2669 was the closest to approaching a significant trend
(p=0.192), with mother clones having a higher average binding. For 2669, mother clones
averaged 2.366% binding and infants averaged 0.535% binding. However, variation in
binding was high among the mother clones with M3 binding similar levels to the infant
clones and preventing a clear trend for transmission from emerging. MIP 2617 had a
similar trend as 2669, where mother clones had a higher average binding (0.928%) than
infants (0.175%). This trend was also not significant (p=0.417). The difference in binding
between mothers and infants can be attributed to one clone (M4) that bound much more
than any other clone. MIP 1084 had similar levels of binding among all clones and the
average binding for mothers was 0.055% and for infants was 0.064%.
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Discussion

Our previous studies showed that V1-V5 of env is capable of influencing
replicative fitness of viral variants from MIP and the fitness is predictive of transmission
[Kong et al, 2008]; however, Env synthesis and processing, viral infectivity, replication
kinetics, and Env incorporation into virions failed to predict transmission [Zhang et al,
2010]. We have also shown that Env fusion does not predict transmission. In this study
we have also shown that viral binding does not predict transmission and cannot account
for the differences that were observed in replicative fitness. As with fusion we can
hypothesize we failed to find a correlation between binding and replicative due in part to
measuring a single round versus multiple rounds of infection.
In all cell types and with all viral preparations we observed variation in binding
abilities from the clones derived from the MIPs. However, we did not see a correlation
between binding activities and fusion activities in any of the clones derived from the
MIP. It is possible that a correlation does not exist, because bound virus is inactivated
due to non-productive endocytosis, endocytosis that does not lead to fusion [Miyauchi et
al, 2009]. Our binding assay may be measuring virus that is bound to CD4, but is
incapable of binding to CCR5 and thus will not complete fusion. Another study found
that monoclonal antibody (MAb) inhibition of HIV-1 entry and fusion did not correlate
with inhibition of binding of a gp120-sCD4 complex to CCR5 positive cells [Olson et al,
1999]. It has been hypothesized that entry has three distinct stages, receptor binding,
coreceptor binding, and fusion. There may be common factors that are capable of
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influencing all three stages, but it is possible that these stages are semi-independent of
each other.
There was a major limitation in our study due to the methodology. There was a
high level of variation between experiments and within experiments; producing a large
standard deviation that remained above the mock infection, but close to these levels. The
major drawback of this methodology appears to be an inability to distinguish a true
positive signal from background. This problem could be due to an over representation of
background (unbound virus that is not washed away), an under representation of bound
virus (cells or virus that is washed away), or a combination of both. These factors could
also account for differences we see between the different viral preparations. We would
expect the same trends to be seen in the EGFP/DsRed2 viruses, the BlaM viruses, and the
viruses without any markers. However, we do not see a repeatable trend. There is a slight
possibility that the addition of the marker to the proviral clones affects the other
biological properties of the viruses and is producing the differences that are observed
between the different viral preparations. For example, we do see a lower viral titer of
viruses containing the BlaM-Vpr fusion protein compared to viruses produced from
proviral constructs without a marker. Another method must be applied to measure viral
binding to confirm our results and draw conclusions about the role viral binding plays
during transmission.
In summary, our data suggests that the Env V1-V5 region derived from subtype C
transmitting MIP is capable of influencing viral binding. However, binding is not
predictive of perinatal transmission, fusion, or replicative fitness. Viral entry into target
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cells is a complicated process that is influenced by multiple factors and it is likely that no
single biological function of Env determines entry or transmission.
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Figure Legend
Figure 1. Relative binding of EGFP/DsRed2 labeled viruses. Binding of viruses
containing the patient Env V1-V5 with EGFP/DsRed2 was done in U87-derived cells.
One day prior to the assay U87 and U87.CD4.CCR5 cells were plated, virus was added
the next day next day and incubated for 1hr at 4ºC. Cells were vigorously washed with
PBS, lysed, and collected. Lysates were clarified by centrifuging at 10,000xg for 10min
and assayed for bound p24 by p24 ELISA as described above. Relative binding is
determined using the U87 cell line to measure background signal (non-specific binding)
and expressed as a fold increase over this level. A. Relative binding of infant (EGFP) and
mother (DsRed2) clones from MIP 1084. B. Average binding of all infant and mother
clones.
Figure 2. Relative binding of viruses from MIP 1084. Binding of viruses containing
the patient Env V1-V5 was done in U87-derived cells. One day prior to the assay U87
and U87.CD4.CCR5 cells were plated, virus was added the next day next day and
incubated for 1hr at 4ºC. Cells were vigorously washed with PBS, lysed, and collected.
Lysates were clarified by centrifuging at 10,000xg for 10min and assayed for bound p24
by p24 ELISA as described above. Relative binding is determined using the U87 cell line
to measure background signal (non-specific binding) and expressed as a fold increase
over this level. A. Relative binding of infant (EGFP) and mother (DsRed2) clones from
MIP 1084. B. Average binding of all infant and mother clones.
Figure 3. Percent binding and fusion of MIP-derived viruses. Both binding and fusion
were done in SupT1-CCR5 cells as described previously. A-C. Percent Binding. Binding
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is calculated as the percentage of input virus that was bound to the cells. D-F. Percent
Fusion. Fusion is calculated as the percent of cells with BlaM activity.
Figure 4. Binding and fusion of infant versus mother viruses. A. Comparison of
binding in infant (

) and mother ( ) variants with patient-derived V1-V5 for each

transmission pair. Average binding is noted with the black bar. B. Comparison of fusion
in infant (

) and mother ( ) variants with patient-derived V1-V5 for each transmission

pair. Average fusion is noted with the black bar
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Table 1. Correlation
between binding and fusion.

MIP

R

R2

2669

0.424

0.180

2617

0.192

0.037

1084

0.027

0.0007
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Conclusion
Our previous study demonstrated that replicative fitness, influenced by the Env
V1-V5 region derived from subtype C transmitting MIP, is predictive of transmission.
Replicative fitness was higher in transmitted infant-derived viruses than non-transmitted
mother-derived viruses. However, no other biological properties of Env that have been
measured are predictive of replicative fitness or perinatal transmission. The current study
sought to determine if fusion and binding activities are influenced by Env V1-V5 and if
any differences correlate to replicative fitness and transmission. We found that neither
fusion nor binding is predictive of transmission. However, we did see clonal variation in
both fusion and binding activities of all MIP Clones studied, demonstrating that Env V1V5 is capable of influencing both activities.
Differences that we observed in fusion of the viral variants from the MIP did not
correlate with transmission, but did correlate with infectivity. We also saw that the
amount of Env incorporated into virions cannot account for differences in fusion
activities. It is likely that the primary genetic sequence of the Env from the MIP, the
structure/stability of the Env from the MIP, or a combination of both factors may play a
role in fusion mediated viral entry into target cells. We also found that fusion and binding
did not correlate, which provides further evidence that entry occurs in distinct stages that
are influenced by different viral and cellular factors.
There are some limitations with our study. The assay we used to measure viral
binding was not yet optimized and additional binding assays should be employed to
confirm these results. There are also a number of follow-up analyses that need to be
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carried out. First, in depth analysis of the Env sequences from the MIP clones should be
performed. Mutagenesis analysis should also be done to determine if any mutations are
capable of influencing either fusion or binding or both. Second, the location of PNGS
should also be analyzed to determine if they are influencing fusion or binding. Third, the
structural analysis should be done to determine the stability of the gp120-gp41 complex
of the Env derived from the MIPs. Nevertheless, the data from this study have provided
several avenues of new inquiry to better understand the functional properties of Env and
its role in perinatal transmission.

